Modeling Dengue Immune Responses Mediated by Antibodies: Insights on the Biological Parameters to Describe Dengue Infections

被引:5
作者
Anam, Vizda [1 ]
Sebayang, Afrina Andriani [2 ]
Fahlena, Hilda [2 ]
Knopoff, Damian [1 ]
Stollenwerk, Nico [1 ,3 ]
Soewono, Edy [2 ,4 ]
Aguiar, Maira [1 ,4 ,5 ]
机构
[1] Basque Ctr Appl Math, Bilbao, Spain
[2] Inst Teknol Bandung, Dept Math, Bandung, West Java, Indonesia
[3] Univ Trento, Dipartimento Matemat, Trento, Italy
[4] Inst Teknol Bandung, Ctr Math Modeling & Simulat, Bandung, West Java, Indonesia
[5] Basque Fdn Sci, Ikerbasque, Bilbao, Spain
关键词
DEPENDENT ENHANCEMENT; HEMORRHAGIC-FEVER; HEALTHY-CHILDREN; EFFICACY; VACCINE; VIRUS; AGE;
D O I
10.1155/2022/8283239
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
Dengue fever is a viral mosquito-borne disease, a significant global health concern, with more than one third of the world population at risk of acquiring the disease. Caused by 4 antigenically distinct but related virus serotypes, named DENV-1, DENV-2, DENV-3, and DENV-4, infection by one serotype confers lifelong immunity to that serotype and a short period of temporary cross immunity to other related serotypes. Severe dengue is epidemiologically associated with a secondary infection caused by a heterologous serotype via the so-called antibody-dependent enhancement (ADE), an immunological process enhancing a new infection. Within-host dengue modeling is restricted to a small number of studies so far. With many open questions, the understanding of immunopathogenesis of severe disease during recurrent infections is important to evaluate the impact of newly licensed vaccines. In this paper, we revisit the modeling framework proposed by Sebayang et al. and perform a detailed sensitivity analysis of the well-known biological parameters and its possible combinations to understand the existing data sets. Using numerical simulations, we investigate features of viral replication, antibody production, and infection clearance over time for three possible scenarios: primary infection, secondary infection caused by homologous serotype, and secondary infection caused by heterologous serotype. Besides, describing well the infection dynamics as reported in the immunology literature, our results provide information on parameter combinations to best describe the differences on the immunological dynamics of secondary infections with homologous and heterologous viruses. The results presented here will be used as baseline to investigate a more complex within-host dengue model.
引用
收藏
页数:11
相关论文
共 27 条
[1]   The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study [J].
Aguiar, Maira ;
Bidaurrazaga Van-Dierdonck, Joseba ;
Mar, Javier ;
Stollenwerk, Nico .
JOURNAL OF ADVANCED RESEARCH, 2022, 39 :157-166
[2]  
Aguiar M, 2022, PHYS LIFE REV, V40, P65, DOI 10.1016/j.plrev.2022.02.001
[3]   The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study [J].
Aguiar, Maira ;
Stollenwerk, Nico .
VACCINES, 2020, 8 (04)
[4]   Dengvaxia: age as surrogate for serostatus [J].
Aguiar, Maira ;
Stollenwerk, Nico .
LANCET INFECTIOUS DISEASES, 2018, 18 (03) :245-245
[5]   Dengvaxia Efficacy Dependency on Serostatus: A Closer Look at More Recent Data [J].
Aguiar, Maira ;
Stollenwerk, Nico .
CLINICAL INFECTIOUS DISEASES, 2018, 66 (04) :641-642
[6]   The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries [J].
Aguiar, Maira ;
Stollenwerk, Nico ;
Halstead, Scott B. .
PLOS NEGLECTED TROPICAL DISEASES, 2016, 10 (12)
[7]   The risks behind Dengvaxia recommendation [J].
Aguiar, Maira ;
Stollenwerk, Nico ;
Halstead, Scott B. .
LANCET INFECTIOUS DISEASES, 2016, 16 (08) :882-883
[8]   The global distribution and burden of dengue [J].
Bhatt, Samir ;
Gething, Peter W. ;
Brady, Oliver J. ;
Messina, Jane P. ;
Farlow, Andrew W. ;
Moyes, Catherine L. ;
Drake, John M. ;
Brownstein, John S. ;
Hoen, Anne G. ;
Sankoh, Osman ;
Myers, Monica F. ;
George, Dylan B. ;
Jaenisch, Thomas ;
Wint, G. R. William ;
Simmons, Cameron P. ;
Scott, Thomas W. ;
Farrar, Jeremy J. ;
Hay, Simon I. .
NATURE, 2013, 496 (7446) :504-507
[9]   Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial [J].
Biswal, Shibadas ;
Borja-Tabora, Charissa ;
Martinez Vargas, Luis ;
Velasquez, Hector ;
Theresa Alera, Maria ;
Sierra, Victor ;
Johana Rodriguez-Arenales, Edith ;
Yu, Delia ;
Wickramasinghe, Pujitha ;
Moreira, Edson Duarte, Jr. ;
Fernando, Asvini D. ;
Gunasekera, Dulanie ;
Kosalaraksa, Pope ;
Espinoza, Felix ;
Lopez-Medina, Eduardo ;
Bravo, Lulu ;
Tuboi, Suely ;
Hutagalung, Yanee ;
Garbes, Pedro ;
Escudero, Ian ;
Rauscher, Martina ;
Bizjajeva, Svetlana ;
LeFevre, Inge ;
Borkowski, Astrid ;
Saez-Llorens, Xavier ;
Wallace, Derek .
LANCET, 2020, 395 (10234) :1423-1433
[10]   Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents [J].
Biswal, Shibadas ;
Reynales, Humberto ;
Saez-Llorens, Xavier ;
Lopez, Pio ;
Borja-Tabora, Charissa ;
Kosalaraksa, Pope ;
Sirivichayakul, Chukiat ;
Watanaveeradej, Veerachai ;
Rivera, Luis ;
Espinoza, Felix ;
Fernando, LakKumar ;
Dietze, Reynaldo ;
Luz, Kleber ;
da Cunha, Rivaldo Venancio ;
Jimeno, Jose ;
Lopez-Medina, Eduardo ;
Borkowski, Astrid ;
Brose, Manja ;
Rauscher, Martina ;
LeFevre, Inge ;
Bizjajeva, Svetlana ;
Bravo, Lulu ;
Wallace, Derek .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2009-2019